Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses + Inotuzumab Ozogamicin+Standard Maintenance Therapy + Imatinib + 6-tioguanine+Standard Maintenance Therapy + Blinatumomab
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Acute Lymphoblastic
Conditions
Leukemia, Acute Lymphoblastic
Trial Timeline
Jul 13, 2020 → Jun 1, 2033
NCT ID
NCT04307576About Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses + Inotuzumab Ozogamicin+Standard Maintenance Therapy + Imatinib + 6-tioguanine+Standard Maintenance Therapy + Blinatumomab
Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses + Inotuzumab Ozogamicin+Standard Maintenance Therapy + Imatinib + 6-tioguanine+Standard Maintenance Therapy + Blinatumomab is a phase 3 stage product being developed by Amgen for Leukemia, Acute Lymphoblastic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04307576. Target conditions include Leukemia, Acute Lymphoblastic.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Acute Lymphoblastic were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04307576 | Phase 3 | Recruiting |
Competing Products
20 competing products in Leukemia, Acute Lymphoblastic